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Summary Background: The AIR II study is a prospective multicentre assessing
management of lower respiratory tract infections (LRTIs) in adults by general
practitioners (GPs). Epidemiological studies generally address the prescriptions of
antibiotics. To our knowledge, little is known about the real impact of non-antibiotic
therapeutic prescriptions (defined here as co-prescriptions) in LRTI. Therefore, the
aim of the study was to evaluate non-antibiotic prescriptions in LRTIs. Methods: Two
thousand general practitioners (GPs) were randomly selected and asked to participate
in each of 30 predefined areas covering mainland France. The patient’s sociomedical
record was completed by the GP during the consultation and sent to the data
processing centre at the same time as an anonymous copy of his prescription. The GP
also had to report the inclusion by telephone and agree to a telephone appointment
with an interviewer. Results: GPs (n ¼ 3144) reported 5469 evaluable cases.
Pneumonia accounted for 9.6% of diagnoses, acute exacerbations of chronic
bronchitis 14.9% and acute bronchitis 72.5%. Antibiotics were prescribed to 96.5%
of patients. In addition to the 5270 prescriptions of antibiotics, co-prescriptions
proved to be twice as numerous as prescriptions of antibiotics (10,027 prescriptions
for 5115 patients). Mucomodifiers, steroidal anti-inflammatory drugs and bronchodi-
lators were significantly more prescribed in AECB than others. Non-steroidal anti-
inflammatory drugs and antitussives were significantly more prescribed in acute
bronchitis than AECB or CAP. Conclusions: Our results suggest that recommendations
of management in LRTIs need to take into account co-prescriptions.
r 2003 Elsevier Ltd. All rights reserved.
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Introduction
Episodes of lower respiratory tract infections (LRTI)
are the most common reason for consulting a
general practitioner (GP).1 LRTI are frequent and
generally include community-acquired pneumonia
(CAP), exacerbation of chronic bronchitis (ECB),
acute bronchitis (AB). LRTI are a major health care
and economic problem due to their high morbidity
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and to the direct and indirect costs that their
management engenders.2 They are usually treated
by antibiotics, although guidelines and recommen-
dations suggest reducing the total volume of
antibiotic prescription.3 Likewise, epidemiological
studies are generally focused on supplementary
investigations and on the prescriptions of antibio-
tics.4,5 While patients’ complaints such as fever,
cough, sputum and dyspnoea lead to symptomatic
treatment prescription by GPs in addition to
antibiotics, little is known about the real magni-
tude of non-antibiotic therapeutic prescriptions
(defined here as co-prescriptions) in LRTI.
The aim of the study was to evaluate manage-
ment of LRTI, focusing on non-antibiotic prescrip-
tion in a large sample from general practice.
Methods
Study design
The methodology of the study has previously been
reported.6 The AIR II study was conducted between
November 1997 and April 1998. Two thousand
general practitioners (GPs) were randomly selected
and asked to participate in each of 30 predefined
areas covering mainland France. The goal was to
obtain a representative sample of at least 200GPs
per area. Some regions were pooled in terms of
geographical proximity into the following
major regions7: North, Brittany, South-West,
South-East, Centre, North-East and Ile de France.
The GPs’ participation was voluntary. Their demo-
graphic data, year of qualification and the char-
acteristics of their practice were obtained by
means of a telephone call from the data processing
centre.
Each GP had to include the first two patients
diagnosed as suffering from LRTI and being seen for
the first time for the current episode, aged between
15 and 65 years and free from cancer, bronchiecta-
sis, hemopathy or tuberculosis. They had to be HIV-
negative. Pregnant women were also excluded.
The patient’s sociomedical record was completed
by the GP during the consultation and sent to the
data processing centre at the same time as an
anonymous copy of his prescription. The GP also
had to report the inclusion by telephone and agree
to a telephone appointment with an interviewer. A
telephone questionnaire enabled the investigator
to collect specific information about the patient,
the supplementary procedures prescribed by the
GP and the reason for his choices. The interview
was conducted on the basis of closed or
multiple-choice questions (reason for consultation,
diagnostic criteria, type of LRTI and auscultatory
symptoms) without any prior recall of the sympto-
matological features usually associated with the
diagnoses. It also included open questions about
the prescriptions of investigations and treatment,
work exemption or follow-up appointments. The
characteristics of severity, such as respiratory or
heart rate, were not recorded insofar as previous
experience had shown that they were not usually
recorded during the consultation. Crackles means
focal signs on chest examination, in favour of
pneumonia. Rhonchi was the bronchial manifesta-
tion of sputum.
Statistical analysis
The ‘‘GP’’ and ‘‘patient’’ files were analysed
separately. Descriptive analyses were undertaken
on each form and were expressed as a percentage
for qualitative variables and as a median for
quantitative variables. Qualitative variables or
those converted to qualitative variables were
analysed with respect to explanatory data relating
to the patients by a bivariate analysis using a w2 or
Fischer’s test. The quantitative variables were
analysed by comparing the means using ANOVA
methods if applicable and by the Kruskall–Wallis
test otherwise. A significance level of 5% was
adopted. The calculations were performed using
BMDP software version 1993 and Digital 8300
hardware.
Results
General practitioners
A more homogeneous distribution was obtained
with 5.6–9.2% of GPs in the sample from each of
these seven major regions. The practice locations
(rural and semi-rural or town o30,000 or 430,000
inhabitants) were each represented by about a
third of the medical population without any bias in
terms of the GPs’ age and gender.
Three thousand one hundred and forty-four GPs
including at least one patient suffering from LRTI
participated in the survey. There was no difference
between their demographic characteristics and
those published in the national statistics from the
National Health Insurance Fund.8
Patients
Five thousand nine hundred and ninety-eight
patients’ records were received, 99 of which
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contained no sociomedical data and 420 failed to
meet the inclusion criteria; 5469 records were
therefore included in the analysis. 84.8% of
patients had additional medical insurance and all
had basic social insurance cover, involving the
general scheme in 84.1% of cases, the agricultural
scheme in 6.5% and the craftsmen and tradesmen’s
scheme in 4.2% (vs. 85%, 10% and 5%, respectively,
according to national statistics).8
Consultations accounted for 73.6% of contacts
and visits 26.4%. The reasons for consultation,
complaints reported by patients and auscultatory
symptoms are presented in Table 1, excluding 214
cases diagnosed as nose infections, so 5354 records
were included.
Co-prescriptions according to patient’
complaints
In addition to the 5270 prescriptions of antibiotics,
multiple co-prescriptions were commonplace
(10,027 prescriptions for 5115 patients). Co-pre-
scriptions proved to be twice as numerous as
prescriptions of antibiotics. Mucomodifiers repre-
sents 32.9% (n ¼ 3299) of co-prescriptions, non-
steroidal anti-inflammatory drugs 31.9%
(n ¼ 3198), antitussives 14.7% (n ¼ 1473), Bronch-
odilators 3.7% (n ¼ 376), rhinitis treatment 13.9%
(n ¼ 1395), and others treatments as homeopathy
2.7%.
In case of antibiotics, prescription was signifi-
cantly higher in patients aged of 45 years old
(97.3%) and more compared with patients o45
years old (95.6%, P ¼ 0:0007). There was no effect
of age of GP’s (P ¼ 0:32). In the same way,
respiratory comorbidity has no effect on antibiotic
prescription (P ¼ 0:28). Prescriptions were lower in
Brittany, North-East, and, South-West (respec-
tively, 94.9%, 94.8%, 94.9%) than other centers
North, South-East, Centre, and Ile de France
(97.5%, 97.8%, 97%, 97.4%, P ¼ 0:0001).
In case of co-prescriptions, we did not find any
significant effect of age, comorbidity or geographic
difference on prescription.
Mucomodifiers were significantly associated with
presence of sputum (Table 2). Non-steroidal anti-
inflammatory drugs (NSAID) were associated with
fever. Steroidal anti-inflammatory drugs (SAID) and
bronchodilators were associated with dyspnoea,
and antitussives were significantly associated with
chest pain.
Co-prescriptions according to auscultatory
symptoms
Mucomodifiers were significantly associated with
rhonchus and NSAID were associated with crackles.
SAID and bronchodilators were associated with
wheezing (Table 3).
Co-prescriptions according to GP’ diagnosis
Mucomodifiers, SAID and bronchodilators were
significantly more prescribed in AECB than others.
NSAID and antitussives were significantly more
prescribed in AB than in AECB or CAP (Table 4).
Discussion
This study represents a new step in analysing the
reasons for non-antibiotic prescriptions by GPs by
placing them in their usual symptomatological and
sociomedical context. Its originality lies in the fact
that symptoms, supplementary diagnostic proce-
dures, treatment and sociomedical parameters
likely to influence prescriptions, were collected
for the same patients. In addition, these details
were recorded in real time from authentic cases to
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Table 1 Reasons for consultations, patients’
complaints, and prescriptions (n ¼ 5354).
Reason for consultation N (%)
Rhinopharyngeal respiratory
symptoms
989(18.5)
Bronchopulmonary respiratory
symptoms
4478(79.9)
Infectious symptoms 1073(20.0)
Constitutional symptoms 819(15.3)
Patients’ complaints
Fever 3592(67.1)
Dyspnoea 1270(23.7)
Cough 4711(88)
Sputum 2895(54.1)
Chest pain 640(12)
Other 230(4.3)
Auscultatory symptoms (n ¼ 4497)
Rhonchi 3663(81.5)
Wheezing 1093(24.3)
Crackles 733(16.3)
None 730(16)
Prescriptions
Referral to specialist opinion 66(1.2)
Hospitalisation 29(0.5)
Supplementary investigations 579(10.8)
Sick leave 1312(24.5)
Follow-up appointment 1330(24.8)
Antibiotic 5165(96.5)
Co-prescriptions (at least one) 5115(95.5)
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prevent the bias introduced by declarative or
retrospective studies. Three thousand one hundred
and forty-four GPs agreed to take part voluntarily
and 5469 cases were analysed. The initial calcula-
tion of a representative sample was based on the
frequency of antibiotic prescriptions in 80% of
cases, a figure which was exceeded. It also aimed
to achieve a homogeneous distribution of the
population of GPs across the seven predefined
areas, an objective not reached for all of them.
However, the distribution of GPs and patients was
relatively homogeneous across the country. In
addition, the comparison between the sample of
GPs and the general medical population, as listed
by the National Health Insurance Fund, means that
the sample may be considered as representative on
a national scale. Likewise, the demographic data of
the patients and the respective proportions of the
various health insurance funds, which were very
similar to the national data, are also indicative of
their representativeness. It cannot be ruled out
that the first two LRTI patients consulting their GP
were not in fact included, so a selection bias is
possible. However, this is the case in all studies
using this kind of methodology.5 Moreover, because
the aim of the study was to evaluate the approach
of GPs’ pragmatically, any bias would only have a
limited influence on the results.
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Table 2 Co-prescriptions according to patients’ complaints.
Medications Fever,
N ¼ 3434
Cough,
N ¼ 4507
Sputum,
N ¼ 2744
Dyspnoea,
N ¼ 1208
Chest pain,
N ¼ 608
N (%) N (%) N (%) N (%) N (%)
Mucomodifiers 2146(62.5) 2830(62.3) 1915(69.8)a 784(64.9) 365(60)
NSAID 189(53.6) 2120(47.1) 1197(43.6) 467(8.6)a 318(52.3)
SAID 479(14) 646(14.3) 40(14.7) 381(31.5)a 116(19)
Antitussives 898(26.2) 1233(27.4) 606(22.1) 254(21) 178(29.3)a
Bronchodilators 187(5.4) 277(6.1) 185(6.7) 202(16.7)a 32(5.3)
aPo0.0001.
Table 3 Co-prescriptions according to auscultatory symptoms.
Medications Rhonchus,
N ¼ 3486
Wheezing,
N ¼ 1053
Crackles,
N ¼ 703
N (%) N (%) N (%)
Mucomodifiers 2356(67.6)a 659(62.6) 460(64.5)
NSAID 1548(44.4) 363(34.5) 336(47.1)a
SAID 523(15) 392(37.3)a 125(17.5)
Antitussives 830(23.8) 253(24) 171(24)
Bronchodilators 249(7.1) 225(21.4)a 44(6.2)
aPo0.005.
Table 4 Co-prescriptions according to diagnoses.
Medications Pneumonia,
n ¼ 496
Acute exacerbation
of chronic bronchitis,
n ¼ 762
Acute bronchitis,
n ¼ 3656
Nb (%) Nb (%) Nb (%)
Mucomodifiers 292 (59.5) 539 (71)a 2329 (62.7)
NSAID 225 (45.8) 246 ( 32.5) 1813 (48.9)a
SAID 93 (18.9) 202 (26.6)a 456 (12.3)
Antitussives 122 (24.8) 143 (18.8) 1040 (28)a
Bronchodilators 21 (4.3) 116 (15.3)a 194 (5.2)
aPo0.05.
bNumber of patients receiving at least one of these medications.
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Mucomodifiers are by far the most common co-
prescriptions, involving 70% of patients with spu-
tum and thus 60% of LRTI. The long experience
gained with these products means that their safety
is no longer in doubt, even though a literature
review in 1993 failed to find any solid evidence of
their value.9 However, a meta-analysis evaluated
the effects of oral mucolytics in adults with stable
chronic bronchitis or COPD, and concluded in a
small reduction in acute exacerbations and a
somewhat greater reduction in total number of
days of disability.10 In our study, no questions were
asked the GPs about bronchopulmonary hygiene
physical therapy prescribed. Bronchopulmonary
hygiene therapy is a form of chest physical therapy
including chest percussion and postural drainage to
remove lung secretions. It is commonly used in
patients with both acute and chronic airway
diseases. A recent review concluded in the absence
of evidence to support or contraindicate the use of
this physical therapy in people with chronic
obstructive pulmonary disease and bronchiecta-
sis.11
NSAID were prescribed for fever and chest pain
significantly more frequently compared with other
complaints. About one patient in five had wheez-
ing, an auscultatory symptom which, even more
than dyspnoea, was the main reason for prescribing
a steroid or a bronchodilator. Like the prescriptions
of steroids and bronchodilators, both signs are very
frequent in ECB. In addition, obvious or suspected
asthma may be a reason for prescribing steroids and
bronchodilators. Steroid prescription was signifi-
cantly higher for dyspnoea, wheezing, and exacer-
bation of chronic bronchitis compared with other
groups. However, only 27% of EACB received steroid
prescriptions. This result highlights the lack of
steroid prescription in this case. GPs needs to get
more information about management of EACB,
particularly steroids use. In addition, unfortu-
nately, information on reaction of patient behind
this prescription was not available in our study.
However, AB accounted for a considerable
proportion of these prescriptions (96.5%), in most
cases macrolides (37.1–44.8%), aminopenicillins
(6.3–30.1%), and for others, cephalosporins, quino-
lones and synergystins. The possibility of expiratory
suppression in reaction to the irritation of the
bronchial nerve endings is known in AB,12 although
its incidence has not precisely been evaluated.
Nevertheless, 19% of SAID in pneumonia is very
surprising but may be due to presence of thoracic
pain.
The prescription of antitussives is frequent. GPs
used them less in cases of ECB, an approach that is
consistent with the recommendations, although the
proportion was too high (20%).13 However, their
symptomatic efficacy is questionable when cough-
ing is the result of an acute infection.9 Likewise,
the lack of any drawbacks is doubtful in all cases in
which a cough is thought to be useful (i.e. when it is
productive), even outside the setting of an ECB.
In conclusion, this study highlights the volume of
prescriptions (both antibiotics and co-prescrip-
tions) in response to LRTI. Despite existing recom-
mendations to reduce or improve antibiotics
prescription, there is no evidence-based medicine
for prescriptions for symptomatic treatments. Non-
antibiotic prescriptions appeared to be linked to
the degree of the symptoms, each of which tended
to receive an individual therapeutic response. Our
results suggest that evidence-based medicine re-
commendations are needed for utilization of co-
prescriptions in management of LRTI’s in general
practice.
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